First-Line Treatment of Metastatic Non-small cell Lung Cancer (NSCLC)


Use of first-line (1L) nivolumab in combination with low-dose (1 mg/kg) ipilimumab and limited (2 cycles of platinum-doublet) chemotherapy in certain patients with metastatic NSCLC (mNSCLC) for PD-L1 non-expressors and expressors

The Lynx Group: 2022 Ask The Expert Behl .pdf
Please Click the Issue to Download


This resource provides insights from a medical oncologist who specializes in lung cancer. It provides information on an extended 2-year follow-up analysis of the Checkmate 9LA trial, with a minimum follow-up of 24.4 months. The Checkmate 9LA trial was a randomized, phase 3, open-label study that evaluated OPDIVO + YERVOY plus 2 cycles of platinum-based chemotherapy compared with 4 cycles of platinum-based chemotherapy alone as first-line therapy in patients with stage IV or recurrent with non-small cell lung cancer, no known sensitizing EGFR or ALK aberrations, and an Eastern Cooperative Oncology Group performance status of 0 or 1. The trial evaluated patients regardless of PD-L1 expression and histology.

Download to Continue Reading

Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: